Aliskiren, sold under the brand name Tekturna and also available as a generic medication, is a prescription drug used to lower high blood pressure. It belongs to a small class of medications known as direct renin inhibitors. Unlike ACE inhibitors or angiotensin receptor blockers (ARBs), which interfere with the renin-angiotensin-aldosterone system farther down the biochemical assembly line, aliskiren steps in near the beginning by directly inhibiting renin.
That mechanism makes aliskiren interesting from a pharmacology standpoint, but interesting does not automatically mean appropriate for everyone. The medication carries an important boxed warning involving pregnancy, can raise potassium levels, may affect kidney function, and has several potentially significant drug interactions. Current U.S. hypertension guidelines generally favor thiazide-type diuretics, long-acting dihydropyridine calcium-channel blockers, ACE inhibitors, or ARBs as initial medication choices for most adults, so aliskiren tends to occupy a more specialized place in blood pressure treatment.
This guide explains what Tekturna is used for, how it works, common and serious side effects, interactions, dosing, tablet appearance, pregnancy warnings, monitoring, and practical experiences patients may encounter while taking it.
What Is Aliskiren (Tekturna)?
Aliskiren is an oral antihypertensive medication approved to treat hypertension. Tekturna is the brand-name version. The medication is classified as a direct renin inhibitor.
Renin is an enzyme released primarily by the kidneys when the body senses changes such as reduced blood flow or blood volume. Renin begins a chain reaction that eventually produces angiotensin II, a powerful substance that tightens blood vessels and promotes sodium retention. Both actions can increase blood pressure.
Aliskiren inhibits renin and reduces the formation of angiotensin I and angiotensin II. With less pressure from this system, blood vessels can remain more relaxed and blood pressure can decrease. The drug has an approximate accumulation half-life of 24 hours, supporting once-daily administration.
What Is Aliskiren Used For?
Treatment of High Blood Pressure
The FDA-approved use of Tekturna is the treatment of hypertension, or high blood pressure. It may be prescribed alone or, when medically appropriate, with certain other antihypertensive medications.
Tekturna is approved for adults and for certain children at least 6 years old who weigh 50 kilograms (about 110 pounds) or more. Although research has evaluated aliskiren in some smaller children, the currently available Tekturna tablet strengths do not provide an appropriate approved dose for children weighing less than 50 kilograms.
Lowering blood pressure is important because persistent hypertension can damage blood vessels and major organs over time. Uncontrolled blood pressure increases the risk of stroke, heart disease, heart failure, kidney disease, and other complications. High blood pressure also frequently causes no obvious symptoms, earning its reputation as a problem that can quietly cause damage while its owner feels perfectly fine.
Is Tekturna a First-Line Blood Pressure Medicine?
Not usually. The 2025 ACC/AHA hypertension guideline emphasizes thiazide-type diuretics, long-acting dihydropyridine calcium-channel blockers, ACE inhibitors, and ARBs when initiating antihypertensive medication for most adults.
That does not mean aliskiren is ineffective. It means doctors generally have other medications with broader clinical-outcome evidence and longer histories of first-line use. Tekturna may still be considered when a clinician decides its benefits fit a particular patient’s medical situation.
Aliskiren Dosage
Typical Adult Dose
The recommended starting dosage of Tekturna for hypertension is:
- 150 mg orally once daily.
If blood pressure remains inadequately controlled, a healthcare provider may increase the dose to:
- 300 mg orally once daily.
Doses above 300 mg daily have not produced additional meaningful blood pressure benefit and are associated with a higher incidence of diarrhea. Most of the blood-pressure-lowering effect of a particular dose is achieved within approximately two weeks.
Pediatric Dosing
For approved pediatric use, children must generally be at least 6 years old and weigh 50 kilograms or more. The recommended starting dose is 150 mg once daily, with possible titration to 300 mg daily when clinically appropriate.
Tekturna is contraindicated in children younger than 2 years. Use should also generally be avoided in children 2 to younger than 6 years and in children weighing less than 20 kilograms because aliskiren exposure may be substantially different in very young children.
How Should Tekturna Be Taken With Food?
Consistency matters. Patients should establish a routine pattern regarding meals rather than taking Tekturna with breakfast one day, fasting the next, and following it with a cheeseburger banquet on Saturday.
A high-fat meal can substantially reduce aliskiren absorption. According to prescribing information, high-fat meals reduced average drug exposure and peak concentrations significantly. Take Tekturna according to the meal instructions provided by the prescriber and try to follow the same pattern every day.
What If You Miss a Dose?
Take a missed dose when you remember unless it is nearly time for the next scheduled dose. If the next dose is close, skip the forgotten tablet and resume the normal schedule.
Do not double the dose to compensate. Two tablets do not make yesterday happen again; they simply increase today’s medication exposure.
What Does Tekturna Look Like? Tablet Pictures and Identification
The branded Tekturna tablets described in current prescribing information are available in two strengths:
- Tekturna 150 mg: light pink, biconvex, round tablet with the imprint NVR on one side and IL on the other.
- Tekturna 300 mg: light red, biconvex, ovaloid tablet with the imprint NVR on one side and IU on the other.
Generic aliskiren tablets may look different. For example, one current generic product uses pink round 150-mg tablets marked “E” and “590,” while its 300-mg tablet is brown and ovaloid with “E” and “591.” Appearance can vary by manufacturer.
Never identify a prescription tablet solely from color. Compare the imprint, strength, bottle label, and manufacturer information, or ask a pharmacist when a tablet does not look familiar.
Common Side Effects of Aliskiren
The most prominent common adverse reaction in clinical studies is diarrhea. At the 300-mg dosage, diarrhea occurred in about 2.3% of patients compared with approximately 1.2% receiving placebo.
Other reported effects include:
- Stomach or abdominal discomfort
- Heartburn or indigestion
- Dizziness
- Headache
- Cough
- Rash
- Back pain
- Nausea or vomiting
Clinical studies found gastrointestinal effects were generally mild and rarely caused patients to stop treatment. Some people may notice more dizziness during the early part of therapy, particularly when they are dehydrated, taking diuretics, or already have relatively low blood pressure.
Serious Aliskiren Side Effects
Angioedema and Severe Allergic Reactions
Aliskiren can rarely cause angioedema, involving rapid swelling of areas such as the lips, tongue, face, throat, or airway. Anaphylactic reactions have also been reported.
Difficulty breathing, throat swelling, trouble swallowing, severe facial swelling, or similar symptoms require emergency medical attention. The drug should not simply be restarted after such a reaction without medical direction.
Low Blood Pressure
Symptomatic hypotension can occur, particularly in people who are depleted of fluid or sodium. Severe vomiting, prolonged diarrhea, heavy sweating, inadequate fluid intake, or intensive diuretic therapy can increase the risk.
Symptoms may include dizziness, weakness, blurred vision, lightheadedness, or fainting.
Kidney Problems
Because aliskiren modifies the renin-angiotensin-aldosterone system, kidney function can change during treatment. Rarely, acute kidney injury may occur, especially in vulnerable patients.
Risk can be higher in patients with kidney disease, renal artery stenosis, severe heart failure, dehydration, or those using certain interacting drugs such as NSAIDs.
High Potassium
Aliskiren can increase serum potassium, resulting in hyperkalemia. Risk factors include kidney impairment, diabetes, potassium supplements, potassium-sparing diuretics, NSAID use, and combination treatment with other drugs affecting the renin-angiotensin system.
Very high potassium can interfere with normal heart rhythm. Patients may require periodic blood tests for potassium and kidney function during treatment.
Severe Skin Reactions
Serious postmarketing skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Blistering, peeling skin, widespread rash, or sores involving mucous membranes require urgent medical evaluation.
Critical Pregnancy Warning
Tekturna carries an FDA boxed warning for fetal toxicity.
Drugs acting directly on the renin-angiotensin system can cause serious injury or death to a developing fetus. Exposure later in pregnancy can reduce fetal kidney function and contribute to low amniotic fluid, impaired lung development, skeletal abnormalities, neonatal kidney failure, hypotension, and death.
When pregnancy is detected, prescribing information states that Tekturna should be discontinued as soon as possible. Anyone who is pregnant, planning pregnancy, or becomes pregnant while taking aliskiren should contact their healthcare provider promptly to arrange appropriate blood pressure treatment.
Breastfeeding
Current prescribing information states that breastfeeding is not recommended during treatment with aliskiren. Discuss alternatives with a healthcare professional if breastfeeding is planned.
Aliskiren Drug Interactions
ACE Inhibitors and ARBs
This is one of the most important interactions.
Combining aliskiren with an ACE inhibitor or ARB can increase the risk of:
- Kidney impairment
- Acute kidney failure
- High potassium
- Excessively low blood pressure
The combination is contraindicated in patients with diabetes. In general, combined use should also be avoided, particularly in patients with impaired kidney function.
Cyclosporine and Itraconazole
Cyclosporine and the antifungal medication itraconazole can significantly increase aliskiren concentrations. Current Tekturna labeling recommends avoiding these combinations.
NSAID Pain Relievers
NSAIDs such as ibuprofen and naproxen may reduce aliskiren’s blood-pressure-lowering effect. They can also increase the risk of worsening kidney function, especially in older adults, dehydrated patients, people taking diuretics, and patients who already have impaired renal function.
Potassium Supplements and Salt Substitutes
Patients should not casually add potassium supplements or potassium-containing salt substitutes while taking Tekturna. Combining them may push potassium levels too high, particularly in people with kidney disease.
Potassium-Sparing Diuretics
Medications that retain potassium can further increase hyperkalemia risk. Examples include spironolactone and similar potassium-sparing therapies. Combining medications may still be appropriate in carefully selected circumstances, but laboratory monitoring becomes particularly important.
Furosemide
Aliskiren can decrease exposure to furosemide, a commonly used loop diuretic. A clinician may therefore monitor the diuretic response after aliskiren is introduced.
Who Should Not Take Tekturna?
Tekturna is contraindicated or inappropriate in several situations. Important examples include:
- Pregnancy because of fetal toxicity
- Diabetes combined with an ACE inhibitor or ARB
- Known hypersensitivity to aliskiren or product ingredients
- Children younger than 2 years
Extra caution and monitoring may be necessary in people with kidney impairment, heart failure, dehydration, a history of angioedema, high potassium levels, or treatment with medications capable of affecting kidney function or potassium.
Monitoring While Taking Aliskiren
Blood pressure is only one part of monitoring. Depending on medical history and concurrent drugs, clinicians may periodically check:
- Blood pressure readings
- Serum creatinine and kidney function
- Blood potassium
- Other electrolytes
- Symptoms suggesting hypotension or dehydration
Home blood pressure measurements can also be useful. The 2025 U.S. hypertension guideline recommends home monitoring as part of blood pressure management when appropriate.
Practical Experiences With Aliskiren: What Taking Tekturna May Be Like
There is no single “Tekturna experience.” Two patients taking exactly 150 mg can have very different responses depending on baseline blood pressure, kidney function, diet, other prescriptions, age, hydration, and individual sensitivity. Still, several practical patterns help explain what treatment may look like outside a textbook.
Experience 1: Blood Pressure Improves Before You Feel Different
Imagine a patient starting Tekturna 150 mg because repeated blood pressure measurements remain elevated. During the first several days, the patient may feel exactly the same.
That is perfectly plausible. High blood pressure itself is frequently symptom-free, and lowering it does not necessarily create an obvious physical sensation. Instead, home readings may gradually improve while the person wonders whether the little pink tablet is doing anything at all.
Most of the effect from a particular aliskiren dosage is expected within approximately two weeks. This is why clinicians generally assess readings over time rather than declaring victory or defeat after two mornings.
Experience 2: Consistent Meal Timing Matters More Than Expected
Another patient may take Tekturna before breakfast Monday through Friday but swallow it after a large weekend brunch on Saturday and Sunday. Because high-fat meals substantially reduce aliskiren absorption, inconsistent meal patterns can introduce unnecessary variability.
A simple routine can help: same approximate time, same relationship to meals, every day. Medication schedules tend to work better when they are boring. In pharmacology, boring is often a compliment.
Experience 3: Diarrhea Appears After the Dose Is Increased
A person may tolerate 150 mg well but develop annoying diarrhea after the clinician raises the dose to 300 mg. This does not prove that aliskiren caused the symptom, but diarrhea is dose-related and is the medication’s most prominent common adverse reaction.
Persistent gastrointestinal symptoms deserve discussion with the prescriber, particularly when diarrhea creates dehydration. Dehydration can amplify the blood-pressure-lowering effect and increase the risk of dizziness or kidney problems.
Experience 4: The “Healthy” Salt Substitute Surprise
Someone trying to reduce sodium may purchase a salt substitute without realizing that many substitutes use potassium chloride. Ordinarily, replacing sodium may sound heart-friendly. With a medication capable of raising potassium, however, adding large amounts of supplemental potassium can become a problem.
This is why medication counseling often includes a seemingly mundane instruction: show your doctor or pharmacist your supplements, electrolyte powders, and salt substitutes too. The pharmacy counter cares about more than prescription bottles.
Experience 5: Ibuprofen Becomes More Complicated
Consider an older adult taking Tekturna who develops knee pain and begins using ibuprofen every day. NSAIDs can interfere with blood pressure control and, in susceptible patients, contribute to deterioration in kidney function when combined with medications affecting the renin-angiotensin system.
An occasional NSAID dose and prolonged daily NSAID therapy are not automatically equivalent risks, but patients should avoid assuming that an over-the-counter label means “interaction-free.” Pharmacists can help identify safer pain-management options based on an individual’s medical conditions.
Experience 6: Laboratory Tests Matter Even When You Feel Fine
A patient may have no symptoms while potassium or creatinine begins moving outside the desired range. That is precisely why periodic laboratory monitoring matters. Kidney impairment and hyperkalemia do not always announce themselves with flashing warning lights.
Keeping scheduled blood tests, recording home blood pressure readings, and reporting major illness, vomiting, diarrhea, dehydration, new medications, or supplements gives the healthcare team much better information for adjusting treatment safely.
The Practical Takeaway
The best experience with aliskiren is usually not dramatic. It is a routine: take the prescribed dose consistently, monitor blood pressure, complete recommended laboratory testing, watch for dizziness or swelling, avoid problematic drug combinations, and communicate changes in medications or health status.
Patients should never change the dose simply because today’s reading is high or skip medication because today’s reading looks excellent unless their clinician has provided specific instructions. Blood pressure management works on trends, not one rebellious number after coffee, traffic, and three emails labeled “URGENT.”
Frequently Asked Questions
How Quickly Does Tekturna Work?
Blood pressure may begin decreasing earlier, but approximately 85% to 90% of the effect of a given dosage is achieved within about two weeks.
Can I Stop Aliskiren Suddenly?
Clinical studies did not demonstrate rebound hypertension after discontinuation, but patients should still speak with their healthcare provider before stopping prescribed blood pressure medication. Blood pressure can gradually rise again when treatment is removed.
Does Aliskiren Cause a Cough?
Cough can occur. Clinical trials found it somewhat more frequently with Tekturna than placebo, although cough occurred less frequently than with ACE inhibitors in comparative studies.
Can Tekturna Damage the Kidneys?
Kidney function can worsen in susceptible individuals. Risk is particularly important in patients with kidney disease, volume depletion, renal artery stenosis, heart failure, certain drug combinations, or NSAID use. Periodic kidney function monitoring may therefore be appropriate.
Can You Drink Alcohol With Aliskiren?
Alcohol may contribute to dizziness or lower blood pressure in some people. Patients should discuss alcohol consumption with their healthcare provider, particularly when first starting treatment or when taking several blood-pressure-lowering medications.
Conclusion
Aliskiren (Tekturna) lowers blood pressure by directly inhibiting renin, an early component of the renin-angiotensin-aldosterone system. The usual starting dose is 150 mg once daily, with a maximum routinely recommended dose of 300 mg once daily. Consistent administration in relation to meals is important because high-fat meals can substantially reduce absorption.
For most people starting hypertension treatment today, aliskiren is not the typical first-line choice. Nevertheless, it remains an FDA-approved antihypertensive option that may be useful in selected patients.
Its most important precautions should not be treated as fine print. Tekturna can harm a developing fetus, can raise potassium, may affect kidney function, and should not be combined with ACE inhibitors or ARBs in patients with diabetes. Cyclosporine and itraconazole should generally be avoided, and medications such as NSAIDs, potassium supplements, salt substitutes, and certain diuretics deserve careful review.
Note: This article is educational and does not replace individualized medical advice, diagnosis, or prescribing instructions. Do not start, stop, or change aliskiren or another blood pressure medication without consulting a qualified healthcare professional.
